ERBB2 and breast carcinoma: Our investigation adopted a multipronged strategy comprising overexpression, RNA interference, and protein-protein interaction inhibitors of BAG-1 to examine BAG-1 function in HER2+ breast cancer cells and to explore whether combination of BAG-1-targeted therapies with trastuzumab could restrict growth of these cells more effectively than trastuzumab monotherapy.